---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-019604"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2023-05-24T23:59:59+00:00"
generated_at: "2026-06-14T15:37:39.188735+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cumberland Pharmaceuticals dismisses FORVIS as auditor, appoints CRI for FY2023

## Summary
- Effective May 18, 2023, dismissed FORVIS as independent auditor; new auditor is Carr, Riggs & Ingram (CRI) subject to engagement letter.
- No disagreements on accounting principles, financial statement disclosure, or audit scope during 2021-2022 and interim 2023.
- FORVIS audit reports for 2021 and 2022 were unqualified, no adverse opinion or modification.
- Company provided FORVIS with disclosures; FORVIS furnished letter to SEC agreeing with statements (Exhibit 16.1).
- No consultations with CRI regarding accounting principles or disagreements prior to appointment.

## SEC filing metadata
- accession: 0001628280-23-019604
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2023-05-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 4.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828023019604/0001628280-23-019604-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828023019604/cpix-20230524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-019604
- JSON: https://secwatch.observer/filing/0001628280-23-019604.json
- Plain text: https://secwatch.observer/filing/0001628280-23-019604.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.